Multiple Myeloma Clinical Trials in Philadelphia

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
J
Active, not recruiting
  • Multiple Myeloma
  • Daratumumab Subcutaneous (SC) Administration
  • Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
  • Atlanta, Georgia
  • +11 more
2021-12-02
Dec 2, 2021
J
Active, not recruiting
  • Multiple Myeloma
  • Little Rock, Arkansas
  • +56 more
2021-12-02
Dec 2, 2021
P
Active, not recruiting
  • Multiple Myeloma
  • Gilbert, Arizona
  • +15 more
2021-11-18
Nov 18, 2021
O
Active, not recruiting
  • Multiple Myeloma
  • Tucson, Arizona
  • +104 more
2021-11-17
Nov 17, 2021
C
Recruiting
  • Multiple Myeloma
  • bb2121
  • +8 more
  • Birmingham, Alabama
  • +50 more
2021-11-10
Nov 10, 2021
U
Recruiting
  • Multiple Myeloma
  • Philadelphia, Pennsylvania
    University of Pennsylvania
2021-11-03
Nov 3, 2021
T
Recruiting
  • Non-Small Cell Lung Cancer
  • +5 more
  • CART-TnMUC1
  • +2 more
  • Phoenix, Arizona
  • +9 more
2021-11-02
Nov 2, 2021
N
Completed
  • Multiple Myeloma
  • One Autologous Transplant
  • +5 more
  • Birmingham, Alabama
  • +35 more
2021-10-19
Oct 19, 2021
M
Not yet recruiting
  • Multiple Myeloma
  • Lenalidomide and bb2121
  • Duarte, California
  • +14 more
2021-10-14
Oct 14, 2021